SLC2A13

Across TCGA pan-cancer cohorts, SLC2A13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC2A13 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLC2A13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC2A13 expression acts as an unfavorable survival marker.

LUAD, HNSC, and LSCC are the cancer types where SLC2A13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.877	1.000	<.001	28	view →
HNSC	DFS	Quartile	II,III,IV	0.528	0.911	.006	27	view →
LSCC	DFS	Median	II,III,IV	0.837	1.000	.006	7	view →
CCRCC	DFS	Tertile	All	0.648	0.872	.048	2	view →
PDAC	DFS	Median	All	0.730	0.796	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC2A13–LUAD (DFS)

Open the LUAD breakdown →